Experimental Cell Biology · 2008 · 49 citations · 0 references
MedicineImmunologyOncologyCancer ImmunologyCarcinogenesisTumor ImmunologyCancer ImmunotherapyCytokines In Tumor ImmunityTumor ImmunopathologyIntraperitoneal AdministrationTumor Necrosis Factor Therapy
A partially purified glycoprotein fraction (the G-200 II fraction) obtained from sera of CD-1 mice sensitized with Corynebacterium parvum and treated with endotoxin was designated as tumor necrosis factor (TNF). Human melanoma cells exposed to this factor in vitro had decreased tumorigenicity when injected into nude mice. Human melanoma, embryonal adenocarcinoma of the testis and colon carcinoma heterotransplanted in nude mice exhibited regressions in size following intraperitoneal injections of TNF. The responses were related to dose and duration of exposure.